原発性骨髄線維症の世界市場レポート2025年

原発性骨髄線維症市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR6.2％で10億7,000万米ドルに成長します。今後の成長要因としては、革新的な治療パイプラインの拡大、疾患の進行を変える治療法に対する需要の高まり、高齢者層における罹患率の増加、併用治療アプローチへのシフト、製薬バイオテクノロジー企業による投資水準の向上などが挙げられます。主要新たな動向としては、精密薬剤開発の進展、診断における次世代シーケンス（NGS）の利用、技術を駆使した患者モニタリングツール、多剤併用療法レジメンの進歩、骨髄線維症の画像診断法の改善などが挙げられます。

骨髄線維症の有病率の増加は、今後数年間の原発性骨髄線維症市場の拡大を促進すると予想されます。骨髄線維症は希少な骨髄がんであり、正常な血液細胞の産生を阻害することで骨髄に大きな瘢痕を生じさせ、その結果、重度の貧血、疲労、衰弱、脾臓肥大を引き起こします。この疾患は、世界人口の高齢化に伴い、60歳以上の高齢者に多く発症しています。平均寿命が延びるにつれ、診断される症例数も増加の一途をたどっています。このような有病率の増加は、調査の促進、早期診断の奨励、治療選択肢の拡大、臨床ガイドラインや治療戦略の改善など、原発性骨髄線維症管理の進歩を支えています。例えば、2024年11月、英国の独立行政法人であるNational Institute for Health and Care Excellenceは、英国における骨髄線維症の有病率は10万人あたり3.2人、発症率は10万人あたり0.6人であると報告しました。その結果、症例数の増加が原発性骨髄線維症市場の成長に寄与しています。

原発性骨髄線維症市場の主要参入企業は、症状をよりよく管理し、病気の進行を遅らせるために、ヤヌスキナーゼ2（JAK2）阻害錠などの革新的な治療法の開発を重視しています。これらの経口薬は、原発性骨髄線維症の過剰な血球産生をもたらす異常なシグナル伝達経路に関与するJAK2酵素を阻害することにより作用します。JAK2阻害剤は、脾臓を小さくし、疲労や骨の痛みを和らげ、病気の進行を遅らせるのに役立ちます。例えば、2025年3月、韓国の製薬バイオテクノロジー企業であるGlaxoSmithKline Korea (GSK Korea) Ltd.は、骨髄線維症の新しい治療であるオムジャラ（モメロチニブ）を発表しました。韓国食品医薬品安全省の承認を受けたOmjaraは、中等度から重度の貧血に苦しむ、中リスクまたは高リスクの原発性または二次性骨髄線維症の成人患者を対象としています。この経口療法は、JAK1、JAK2、アクチビンA受容体1型（ACVR1）を標的とし、貧血、脾腫、疲労などの症状を効果的に治療します。臨床検査の結果、既存の治療と比較してこれらの領域で有意な改善が認められ、本薬の承認を支持するものです。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、貿易戦争と関税、コロナ禍と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界の原発性骨髄線維症：PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の原発性骨髄線維症市場：成長率分析
• 世界の原発性骨髄線維症市場の実績：規模と成長、2019～2024年
• 世界の原発性骨髄線維症市場の予測：規模と成長、2024～2029年、2034年
• 世界の原発性骨髄線維症：総潜在市場規模（TAM）

第6章 市場セグメンテーション

• 世界の原発性骨髄線維症市場：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 脊髄小脳原発性骨髄線維症
• 原発性骨髄線維症・毛細血管拡大症
• エピソード性原発性骨髄線維症
• その他
• 世界の原発性骨髄線維症市場：サービス別、実績と予測、2019～2024年、2024～2029年、2034年
• 治療
• 診断
• 世界の原発性骨髄線維症市場：剤形別、実績と予測、2019～2024年、2024～2029年、2034年
• 固体
• 液体
• その他
• 世界の原発性骨髄線維症市場：年齢層別、実績と予測、2019～2024年、2024～2029年、2034年
• 成人
• 幼児
• 高齢者
• 世界の原発性骨髄線維症市場：エンドユーザー別、実績と予測、2019～2024年、2024～2029年、2034年
• 病院
• クリニック
• その他
• 世界の原発性骨髄線維症市場、脊髄小脳原発性骨髄線維症の病型別サブセグメンテーション、タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 脊髄小脳失調症と骨髄線維症
• 遺伝性脊髄小脳変性症（骨髄線維症を伴う）
• 線維化を伴う神経変性脊髄小脳症候群
• 世界の原発性骨髄線維症市場、原発性骨髄線維症・毛細血管拡大症のサブセグメンテーション、タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 骨髄線維症を伴う皮膚毛細血管拡大症
• 遺伝性出血性毛細血管拡大症と骨髄線維症
• 眼毛細血管拡大症関連骨髄線維症
• 世界の原発性骨髄線維症市場、エピソード性原発性骨髄線維症の病型別サブセグメンテーション、タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 間欠性骨髄線維症エピソード
• 線維化の悪化を伴う周期性血球減少症
• 自己免疫疾患における周期性骨髄線維症
• 世界の原発性骨髄線維症市場、その他のタイプのサブセグメンテーション、タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 家族性原発性骨髄線維症
• 特発性骨髄線維症
• セラピー関連の原発性骨髄線維症
• 若年性原発性骨髄線維症

第7章 地域別・国別分析

• 世界の原発性骨髄線維症市場：地域別、実績と予測、2019～2024年、2024～2029年、2034年
• 世界の原発性骨髄線維症市場：国別、実績と予測、2019～2024年、2024～2029年、2034年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 原発性骨髄線維症市場：競合情勢
• 原発性骨髄線維症市場：企業プロファイル
  • Merck & Co. Inc.
  • AbbVie Inc.
  • Bristol-Myers Squibb Company
  • Sumitomo Pharma Oncology Inc.
  • Incyte Corporation

第31章 その他の大手企業と革新的企業

• Nippon Shinyaku Co. Ltd.
• MorphoSys AG
• Keros Therapeutics Inc.
• Geron Corporation
• Lynk Pharmaceuticals Co. Ltd.
• Pharmaxis Ltd
• Kartos Therapeutics Inc.
• Disc Medicine Inc.
• Galecto Inc.
• Cellenkos Inc.
• Chia Tai Tianqing Pharmaceutical Group Co. Ltd.
• Taiga BIoTechnologies Inc.
• Suzhou Zelgen Biopharmaceuticals Co. Ltd.
• Telios Pharma Inc.
• Samus Therapeutics Inc.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、戦略

• 原発性骨髄線維症市場、2029年：新たな機会を提供する国
• 原発性骨髄線維症市場、2029年：新たな機会を提供するセグメント
• 原発性骨髄線維症市場、2029年：成長戦略
  • 市場動向による戦略
  • 競合の戦略

第36章 付録

Primary myelofibrosis (PMF) is a rare and chronic bone marrow condition marked by the excessive development of fibrous scar tissue (fibrosis) within the bone marrow. This fibrosis interferes with the normal production of blood cells, resulting in symptoms such as anemia, fatigue, weakness, and an enlarged spleen (splenomegaly). PMF falls under the category of myeloproliferative neoplasms (MPNs) and can also lead to issues like night sweats, unintended weight loss, and bone discomfort.

The major types of primary myelofibrosis include spinocerebellar primary myelofibrosis, primary myelofibrosis-telangiectasia, episodic primary myelofibrosis, and other less common forms. Services provided encompass both diagnosis and treatment, while medication options are offered in multiple dosage forms, including solids, liquids, and other formulations, to cater to various patient needs. This condition can affect individuals of all age groups-children, adults, and the elderly-and is managed in various healthcare environments such as hospitals, clinics, and other care facilities.

The primary myelofibrosis market research report is one of a series of new reports from The Business Research Company that provides primary myelofibrosis market statistics, including the primary myelofibrosis industry global market size, regional shares, competitors with the primary myelofibrosis market share, detailed primary myelofibrosis market segments, market trends, and opportunities, and any further data you may need to thrive in the primary myelofibrosis industry. These primary myelofibrosis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The primary myelofibrosis market size has grown strongly in recent years. It will grow from $0.79 billion in 2024 to $0.84 billion in 2025 at a compound annual growth rate (CAGR) of 6.4%. Growth during the historic period was driven by greater awareness of the disease among healthcare providers, expanded use of JAK inhibitors, improved diagnostic and genetic testing capabilities, enhanced access to hematology care, and a rise in clinical research activity.

The primary myelofibrosis market size is expected to see strong growth in the next few years. It will grow to $1.07 billion in 2029 at a compound annual growth rate (CAGR) of 6.2%. Contributing factors to future growth include the expansion of innovative treatment pipelines, rising demand for therapies that alter disease progression, increasing incidence among elderly populations, a shift toward combination treatment approaches, and higher levels of investment from pharmaceutical and biotechnology companies. Key emerging trends include progress in precision drug development, the use of next-generation sequencing (NGS) in diagnostics, tech-enabled patient monitoring tools, advancements in multi-drug therapy regimens, and improvements in imaging methods for bone marrow fibrosis.

The growing prevalence of myelofibrosis is anticipated to drive the expansion of the primary myelofibrosis market in the coming years. Myelofibrosis is a rare bone marrow cancer that interferes with the normal production of blood cells, leading to significant scarring in the bone marrow, which in turn causes severe anemia, fatigue, weakness, and an enlarged spleen. This condition is increasingly prevalent due to the aging global population, as it most commonly affects individuals over the age of 60. With life expectancy on the rise, the number of diagnosed cases continues to grow. This increase in prevalence supports advancements in primary myelofibrosis management by promoting research, encouraging early diagnosis, expanding treatment options, and refining clinical guidelines and care strategies. For example, in November 2024, the National Institute for Health and Care Excellence, a UK-based independent executive non-departmental public body, reported that myelofibrosis has a prevalence of 3.2 per 100,000 people in the UK and an incidence rate of 0.6 per 100,000. As a result, the increasing number of cases is contributing to the growth of the primary myelofibrosis market.

Key players in the primary myelofibrosis market are emphasizing the development of innovative treatments such as Janus kinase 2 (JAK2) inhibiting tablets to better manage symptoms and slow disease progression. These oral medications work by blocking the JAK2 enzyme, which is involved in abnormal signaling pathways that result in excessive blood cell production in primary myelofibrosis. JAK2 inhibitors help reduce spleen size, relieve fatigue and bone pain, and slow disease progression. For instance, in March 2025, GlaxoSmithKline Korea (GSK Korea) Ltd., a pharmaceutical and biotechnology company based in South Korea, introduced Omjjara (momelotinib), a new treatment for myelofibrosis. Approved by South Korea's Ministry of Food and Drug Safety, Omjjara is designed for adult patients with intermediate- or high-risk primary or secondary myelofibrosis who suffer from moderate to severe anemia. This oral therapy targets JAK1, JAK2, and activin A receptor type 1 (ACVR1), effectively treating symptoms such as anemia, splenomegaly, and fatigue. Clinical trial results showed significant improvements in these areas compared to existing treatments, supporting the drug's approval.

In June 2022, GSK plc, a UK-based pharmaceutical and biotechnology firm, completed the acquisition of Sierra Oncology, Inc. for approximately $1.9 billion. This move was intended to strengthen GSK's oncology pipeline, particularly in the area of hematologic cancers. Sierra Oncology, Inc. is a U.S.-based biopharmaceutical company focused on the development of therapies for primary myelofibrosis.

Major players in the primary myelofibrosis market are Merck & Co. Inc., AbbVie Inc., Bristol-Myers Squibb Company, Sumitomo Pharma Oncology Inc., Incyte Corporation, Nippon Shinyaku Co. Ltd., MorphoSys AG, Keros Therapeutics Inc., Geron Corporation, Lynk Pharmaceuticals Co. Ltd., Pharmaxis Ltd, Kartos Therapeutics Inc., Disc Medicine Inc., Galecto Inc., Cellenkos Inc., Chia Tai Tianqing Pharmaceutical Group Co. Ltd., Taiga Biotechnologies Inc., Suzhou Zelgen Biopharmaceuticals Co. Ltd., Telios Pharma Inc., Samus Therapeutics Inc., Jacobio Pharmaceuticals Co. Ltd.

North America was the largest region in the primary myelofibrosis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in primary myelofibrosis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the primary myelofibrosis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The primary myelofibrosis market consists of revenues earned by entities by providing services such as diagnosis services, medical consultations, treatment services, monitoring and follow-up and supportive care. The market value includes the value of related goods sold by the service provider or included within the service offering. The primary myelofibrosis (PMF) market also includes sales of products including ruxolitinib (Jakafi or Jakavi), erythropoiesis-stimulating agents (ESAs), hydroxyurea, bone marrow or stem cell transplant kits and iron supplements. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Primary Myelofibrosis Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on primary myelofibrosis market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for primary myelofibrosis ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The primary myelofibrosis market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Spinocerebellar Primary Myelofibrosiss; Primary Myelofibrosis-Telangiectasia; Episodic Primary Myelofibrosis; Other Types
• 2) By Services: Treatment; Diagnosis
• 3) By Dosage Forms: Solid; Liquids; Other Dosage Forms
• 4) By Age: Adult; Child; Geriatric
• 5) By End User: Hospitals; Clinics; Other End Users
• Subsegments:
• 1) By Spinocerebellar Primary Myelofibrosis: Spinocerebellar Ataxia With Myelofibrosis; Hereditary Spinocerebellar Degeneration With Bone Marrow Fibrosis; Neurodegenerative Spinocerebellar Syndromes With Fibrotic Manifestations
• 2) By Primary Myelofibrosis-Telangiectasia: Cutaneous Telangiectasia With Myelofibrosis; Hereditary Hemorrhagic Telangiectasia With Marrow Fibrosis; Ocular Telangiectasia-Associated Myelofibrosis
• 3) By Episodic Primary Myelofibrosis: Intermittent Marrow Fibrosis Episodes; Periodic Cytopenia With Fibrosis Flare; Cyclical Myelofibrosis In Autoimmune Disorders
• 4) By Other Types: Familial Primary Myelofibrosis; Idiopathic Myelofibrosis; Therapy-Related Primary Myelofibrosis; Juvenile Primary Myelofibrosis
• Companies Mentioned: Merck & Co. Inc.; AbbVie Inc.; Bristol-Myers Squibb Company; Sumitomo Pharma Oncology Inc.; Incyte Corporation
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Primary Myelofibrosis Market Characteristics

3. Primary Myelofibrosis Market Trends And Strategies

4. Primary Myelofibrosis Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Primary Myelofibrosis Growth Analysis And Strategic Analysis Framework

• 5.1. Global Primary Myelofibrosis PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Primary Myelofibrosis Market Growth Rate Analysis
• 5.4. Global Primary Myelofibrosis Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Primary Myelofibrosis Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Primary Myelofibrosis Total Addressable Market (TAM)

6. Primary Myelofibrosis Market Segmentation

• 6.1. Global Primary Myelofibrosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Spinocerebellar Primary Myelofibrosiss
• Primary Myelofibrosis-Telangiectasia
• Episodic Primary Myelofibrosis
• Other Types
• 6.2. Global Primary Myelofibrosis Market, Segmentation By Services, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Treatment
• Diagnosis
• 6.3. Global Primary Myelofibrosis Market, Segmentation By Dosage Forms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Solid
• Liquids
• Other Dosage Forms
• 6.4. Global Primary Myelofibrosis Market, Segmentation By Age, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Adult
• Child
• Geriatric
• 6.5. Global Primary Myelofibrosis Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Clinics
• Other End Users
• 6.6. Global Primary Myelofibrosis Market, Sub-Segmentation Of Spinocerebellar Primary Myelofibrosis, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Spinocerebellar Ataxia With Myelofibrosis
• Hereditary Spinocerebellar Degeneration With Bone Marrow Fibrosis
• Neurodegenerative Spinocerebellar Syndromes With Fibrotic Manifestations
• 6.7. Global Primary Myelofibrosis Market, Sub-Segmentation Of Primary Myelofibrosis-Telangiectasia, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Cutaneous Telangiectasia With Myelofibrosis
• Hereditary Hemorrhagic Telangiectasia With Marrow Fibrosis
• Ocular Telangiectasia-Associated Myelofibrosis
• 6.8. Global Primary Myelofibrosis Market, Sub-Segmentation Of Episodic Primary Myelofibrosis, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Intermittent Marrow Fibrosis Episodes
• Periodic Cytopenia With Fibrosis Flare
• Cyclical Myelofibrosis In Autoimmune Disorders
• 6.9. Global Primary Myelofibrosis Market, Sub-Segmentation Of Other Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Familial Primary Myelofibrosis
• Idiopathic Myelofibrosis
• Therapy-Related Primary Myelofibrosis
• Juvenile Primary Myelofibrosis

7. Primary Myelofibrosis Market Regional And Country Analysis

• 7.1. Global Primary Myelofibrosis Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Primary Myelofibrosis Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Primary Myelofibrosis Market

• 8.1. Asia-Pacific Primary Myelofibrosis Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Primary Myelofibrosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Primary Myelofibrosis Market, Segmentation By Services, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Primary Myelofibrosis Market, Segmentation By Dosage Forms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Primary Myelofibrosis Market

• 9.1. China Primary Myelofibrosis Market Overview
• 9.2. China Primary Myelofibrosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Primary Myelofibrosis Market, Segmentation By Services, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Primary Myelofibrosis Market, Segmentation By Dosage Forms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Primary Myelofibrosis Market

• 10.1. India Primary Myelofibrosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Primary Myelofibrosis Market, Segmentation By Services, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Primary Myelofibrosis Market, Segmentation By Dosage Forms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Primary Myelofibrosis Market

• 11.1. Japan Primary Myelofibrosis Market Overview
• 11.2. Japan Primary Myelofibrosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Primary Myelofibrosis Market, Segmentation By Services, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Primary Myelofibrosis Market, Segmentation By Dosage Forms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Primary Myelofibrosis Market

• 12.1. Australia Primary Myelofibrosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Primary Myelofibrosis Market, Segmentation By Services, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Primary Myelofibrosis Market, Segmentation By Dosage Forms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Primary Myelofibrosis Market

• 13.1. Indonesia Primary Myelofibrosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Primary Myelofibrosis Market, Segmentation By Services, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Primary Myelofibrosis Market, Segmentation By Dosage Forms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Primary Myelofibrosis Market

• 14.1. South Korea Primary Myelofibrosis Market Overview
• 14.2. South Korea Primary Myelofibrosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Primary Myelofibrosis Market, Segmentation By Services, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Primary Myelofibrosis Market, Segmentation By Dosage Forms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Primary Myelofibrosis Market

• 15.1. Western Europe Primary Myelofibrosis Market Overview
• 15.2. Western Europe Primary Myelofibrosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Primary Myelofibrosis Market, Segmentation By Services, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Primary Myelofibrosis Market, Segmentation By Dosage Forms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Primary Myelofibrosis Market

• 16.1. UK Primary Myelofibrosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Primary Myelofibrosis Market, Segmentation By Services, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Primary Myelofibrosis Market, Segmentation By Dosage Forms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Primary Myelofibrosis Market

• 17.1. Germany Primary Myelofibrosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Primary Myelofibrosis Market, Segmentation By Services, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Primary Myelofibrosis Market, Segmentation By Dosage Forms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Primary Myelofibrosis Market

• 18.1. France Primary Myelofibrosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Primary Myelofibrosis Market, Segmentation By Services, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Primary Myelofibrosis Market, Segmentation By Dosage Forms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Primary Myelofibrosis Market

• 19.1. Italy Primary Myelofibrosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Primary Myelofibrosis Market, Segmentation By Services, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Primary Myelofibrosis Market, Segmentation By Dosage Forms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Primary Myelofibrosis Market

• 20.1. Spain Primary Myelofibrosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Primary Myelofibrosis Market, Segmentation By Services, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Primary Myelofibrosis Market, Segmentation By Dosage Forms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Primary Myelofibrosis Market

• 21.1. Eastern Europe Primary Myelofibrosis Market Overview
• 21.2. Eastern Europe Primary Myelofibrosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Primary Myelofibrosis Market, Segmentation By Services, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Primary Myelofibrosis Market, Segmentation By Dosage Forms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Primary Myelofibrosis Market

• 22.1. Russia Primary Myelofibrosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Primary Myelofibrosis Market, Segmentation By Services, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Primary Myelofibrosis Market, Segmentation By Dosage Forms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Primary Myelofibrosis Market

• 23.1. North America Primary Myelofibrosis Market Overview
• 23.2. North America Primary Myelofibrosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Primary Myelofibrosis Market, Segmentation By Services, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Primary Myelofibrosis Market, Segmentation By Dosage Forms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Primary Myelofibrosis Market

• 24.1. USA Primary Myelofibrosis Market Overview
• 24.2. USA Primary Myelofibrosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Primary Myelofibrosis Market, Segmentation By Services, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Primary Myelofibrosis Market, Segmentation By Dosage Forms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Primary Myelofibrosis Market

• 25.1. Canada Primary Myelofibrosis Market Overview
• 25.2. Canada Primary Myelofibrosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Primary Myelofibrosis Market, Segmentation By Services, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Primary Myelofibrosis Market, Segmentation By Dosage Forms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Primary Myelofibrosis Market

• 26.1. South America Primary Myelofibrosis Market Overview
• 26.2. South America Primary Myelofibrosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Primary Myelofibrosis Market, Segmentation By Services, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Primary Myelofibrosis Market, Segmentation By Dosage Forms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Primary Myelofibrosis Market

• 27.1. Brazil Primary Myelofibrosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Primary Myelofibrosis Market, Segmentation By Services, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Primary Myelofibrosis Market, Segmentation By Dosage Forms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Primary Myelofibrosis Market

• 28.1. Middle East Primary Myelofibrosis Market Overview
• 28.2. Middle East Primary Myelofibrosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Primary Myelofibrosis Market, Segmentation By Services, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Primary Myelofibrosis Market, Segmentation By Dosage Forms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Primary Myelofibrosis Market

• 29.1. Africa Primary Myelofibrosis Market Overview
• 29.2. Africa Primary Myelofibrosis Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Primary Myelofibrosis Market, Segmentation By Services, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Primary Myelofibrosis Market, Segmentation By Dosage Forms, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Primary Myelofibrosis Market Competitive Landscape And Company Profiles

• 30.1. Primary Myelofibrosis Market Competitive Landscape
• 30.2. Primary Myelofibrosis Market Company Profiles
  • 30.2.1. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Sumitomo Pharma Oncology Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Incyte Corporation Overview, Products and Services, Strategy and Financial Analysis

31. Primary Myelofibrosis Market Other Major And Innovative Companies

• 31.1. Nippon Shinyaku Co. Ltd.
• 31.2. MorphoSys AG
• 31.3. Keros Therapeutics Inc.
• 31.4. Geron Corporation
• 31.5. Lynk Pharmaceuticals Co. Ltd.
• 31.6. Pharmaxis Ltd
• 31.7. Kartos Therapeutics Inc.
• 31.8. Disc Medicine Inc.
• 31.9. Galecto Inc.
• 31.10. Cellenkos Inc.
• 31.11. Chia Tai Tianqing Pharmaceutical Group Co. Ltd.
• 31.12. Taiga Biotechnologies Inc.
• 31.13. Suzhou Zelgen Biopharmaceuticals Co. Ltd.
• 31.14. Telios Pharma Inc.
• 31.15. Samus Therapeutics Inc.

32. Global Primary Myelofibrosis Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Primary Myelofibrosis Market

34. Recent Developments In The Primary Myelofibrosis Market

35. Primary Myelofibrosis Market High Potential Countries, Segments and Strategies

• 35.1 Primary Myelofibrosis Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Primary Myelofibrosis Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Primary Myelofibrosis Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer